INZ-701 for Calciphylaxis

Calciphylaxis, or calcific uremic arteriopathy, is a rare but serious disease that mostly affects patients with end-stage kidney disease. It is characterized by painful sores and wounds that are hard to heal, and no approved therapies exist. Low levels of inorganic pyrophosphate (PPi) are associated with the development of calciphylaxis, and also with related morbidity and mortality. Interim data of the SEAPORT 1 trial presented at ASN Kidney Week 2024 showed that Inozyme’s therapy INZ-701 addresses PPi deficiency to potentially modify the course of the disease. Nephrology Times spoke with co-author Sagar Nigwekar, MD, MMSc, about the promising findings.